MARR CONSULTANCY: Andrew Marr assesses the changes and impacts of the revised XEVMPD guidance of 5 March 2012

Andrew Marr re-assesses the impact of the revised guidance on XEVMPD issued by EMA on 5 March 2012

EVMPD data are still required to be submitted to EMA for all authorised medicinal products in Europe by 2 July 2012 but the scope of the data required is reduced.

To find more information about this articile please use the below mentioned weblink

http://marrconsultancy.com/2012/03/15/andrew-marr-assesses-the-changes-and-impacts-of-the-revised-xevmpd-guidance-of-5-march-2012/